[1] 孔晓飞,陈成伟.中华医学会第十三次病毒性肝炎与肝病学术会议纪要.肝脏,2007,12:234.
[2] 李杰,庄辉.病毒性肝炎流行病学进展.肝脏,2012,17:2-5.
[3] Zhi X, Deng M, Yang H, et al. A novel HBV genotypes detecting system combined with microfluidic chip, loop-mediated isothermal amplification and GMR sensors. Biosensors Bioelectronics, 2014, 54: 372-377.
[4] 病毒性肝炎防治方案. 中华内科杂志, 2001, 40: 62-68.
[5] 杜黎黎, 李艳, 徐万洲, 等. 慢性肝病患者血脂水平及临床意义. 现代检验医学杂志, 2012, 27: 153-155.
[6] 陈俊杰, 戎奇吉. 慢性肝病患者血清载脂蛋白A检测的临床意义. 浙江预防医学, 2008, 20: 6-7,17.
[7] 徐丽, 刘积平, 张颖, 等. 慢性肝病患者载脂蛋白A1和B的变化. 武警医学院学报, 2003, 12: 214.
[8] Sun L, Li Z, Zhang H, et al. Pentanucleotide TTTTA repeat polymorphism of apolipoprotein (a) gene and plasma lipoprotein(a) are associated with ischemic and hemorrhagic stroke in chinese a multicenter case-control study in China. Stroke, 2003, 34: 1617-1622.
[9] Jiang Z, Sun S, Liang A, et al. Gold-labeled nanoparticle-based immunoresonance scattering spectral assay for trace apolipoprotein AI and apolipoprotein B. Clin Chem, 2006, 52: 1389-1394.
[10] 王陆军, 杨永平. 肝损伤指数判断慢性肝炎转归的临床意义. 军事医学科学院院刊, 2003, 27: 51-53.
[11] 黄小琪. 肝硬化并发肝性脑病患者载脂蛋白A1、B的检测以及临床意义. 现代预防医学, 2012, 39: 1994-1995. |
